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A b s T r A C T
Phenylketonuria (PKU) is a classical example of an 
inherited metabolic disease, in which mental retardation 
can be prevented successfully by using a diet. However, 
in adult PKU new problems occur, such as vitamin 
deficiencies, osteoporosis and the maternal PKU 
syndrome. The aim of this review article is to provide 
guidelines for the clinician to understand and manage 
PKU in adults.
K E Y W o r d s
Adults, complications, phenylketonuria
i N T r o d U C T i o N
Phenylketonuria (PKU) is a hereditary metabolic disease, 
which is seen in approximately 1:18,000 newborns in the 
Netherlands.1 In most cases it results from a deficiency of 
phenylalanine hydroxylase (PAH), an enzyme necessary 
for the conversion of phenylalanine (Phe) into tyrosine. 
Hyperphenylalaninaemia is the biochemical hallmark 
of PKU. Defects in the recycling of the cofactor required 
for PAH activity, tetrahydrobiopterin (BH4), can result in 
hyperphenylalaninaemia as well (figure 1). BH4 deficiency 
accounts for approximately 2% of the patients with elevated 
Phe levels.2 Since 1974 all newborns in the Netherlands are 
tested for PKU within eight days after birth.1 
The mode of inheritance of PKU is autosomal recessive. 
Nearly all cases are caused by mutations in the gene 
encoding PAH, which has been mapped to human 
chromosome 12q24.1.3 Clinical and molecular studies have 
indicated that PAH deficiency is a highly heterogeneous 
disease.4 To date, more than 400 different mutations have 
been characterised in the PAH gene in various ethnic 
groups. Genotype at the mutant PAH locus influences the 
biochemical phenotype in heterozygotes.5
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If untreated, PKU leads to the development of mental 
retardation and neurological disturbances.6 Hyperactivity 
may occur as well as hypopigmentation and eczematous 
rash. The exact mechanism by which the elevated 
concentration of Phe causes mental retardation is 
unknown. Several hypotheses have been described. High 
Phe values can have a direct deleterious effect on the 
myelinisation in cerebro.7 Another mechanism can be 
the high affinity of Phe for the transport across the 
blood brain barrier. This transporter is also used by e.g. 
tyrosine and tryptophan, which are precursors of dopamine 
and serotonin. Therefore, high Phe concentrations can 
lead to disturbances in dopaminergic and serotonergic 
neurotransmission.8,9
d i A G N o s i s
The diagnosis of PKU is based upon the finding of an 
elevated serum concentration of Phe (reference value 35 to 76 
μmol/l). Classical PKU or just PKU is historically defined as 
a blood Phe level >1200 μmol/l, which indicates a complete 
deficiency of PAH. At that level phenylketones appear in the 
urine. In mild/atypical PKU levels of 600 to 1200 μmol/l 
are seen and hyperphenylalaninaemia (HPA) is classified 
figure 1. The metabolism of phenylalanine
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as blood Phe levels between 240 and 600 μmol/l.10 In the 
Netherlands a successive BH4 loading test is performed 
to detect a possible BH4 deficiency.11 The most useful 
laboratory method for newborn screening is tandem mass 
spectrometry.12 Other methods include the Guthrie bacterial 
assay, fluorometric and chromatographic analysis.
P r i N C i P l E s  o f  T r E A T M E N T
The principle of treatment in PAH deficiency is to reduce 
the blood Phe concentration sufficiently to prevent brain 
damage. The cornerstone of PKU treatment is dietary 
protein restriction, supplemented with all amino acids 
except Phe. It should be initiated as soon as possible after 
diagnosis. 
One of the most controversial issues is whether to stop or 
continue dietary treatment throughout adulthood. Before 
1970, clinicians believed that dietary treatment was only 
necessary until the end of childhood.13,14 The rationale 
for this approach was that the brain is only vulnerable 
to the toxic effects of elevated Phe in the period of its 
maximal myelinisation throughout childhood.15 Later on, 
concerns were raised about the safety of discontinuing 
the diet. Several studies suggested that elevated Phe 
concentrations in adults adversely affect cognitive function, 
neuro psychological and psychiatric outcome.12 Apart from 
in France, this led to the recommendation of ‘diet for life’ 
in most treatment centres, although recommendations 
about blood Phe levels do vary. The actual recommendation 
of ‘diet for life’ is based on lack of sufficient evidence 
to support the relaxation of diet in adults. Channon et 
al. found that after discontinuing the diet, only subtle 
changes in cognitive performance occurred compared with 
adolescents who remained on a diet.16 
According to the Dutch guidelines of management of 
adult PKU, the target blood Phe level is 120 to 600 μmol/l. 
In Germany the target level is 40 to 1200 μmol/l, in 
the UK 120 to 700 μmol/l and in the USA 120 to 900 
μmol/l. In our centre we encourage those on diet to 
monitor regularly (one to three monthly) and take their 
nutritional supplements with the aim to keep the Phe 
level <600 μmol/l. There is a very real risk of vitamin B12 
and other micronutrient deficiencies in those patients 
restricting their protein intake, but not taking vitamin 
supplements. Therefore, for those who choose to be off 
diet, we recommend that they eat a completely normal diet 
with full protein and vitamin intake. Side effects of dietary 
treatment such as vitamin deficiencies and osteoporosis, 
possibly due to long-standing dietary deficiency of protein, 
calcium, vitamin D, vitamin B12 or trace elements, can be 
prevented by this approach. The role of essential fatty acid 
supplementation in the diet of PKU patients remains to 
be explored.
The poor palatability of protein substitutes leads to 
a decrease in compliance with the diet, especially in 
adolescents. Furthermore time constraints, social pressure 
and dissatisfaction with restrictions challenge dietary 
compliance.17 Consequently, the need for an alternative 
treatment is growing. 
Many new approaches have been discovered in the last ten 
years. The most ultimate and definitive therapy for PKU 
patients would be a liver transplantation, because it would 
correct the molecular disorder. But it is too complicated and 
hazardous to be justifiable as an appropriate substitute for 
the diet.18 However, the availability of the classic effective 
treatment militates against a therapy requiring immune 
suppressive therapy, with its attendant complications.
In 1999, it was discovered that some PKU patients can 
benefit from administration of the cofactor BH4. Many 
studies confirmed the decrease on the blood Phe levels.19-21 
In a large study, 38% of the PKU patients (not BH4 deficient) 
responded to BH4 administration with a decrease of ≥30% 
in Phe. The prevalence of responsiveness was unfortunately 
highest in patients with mild forms of PKU. Only 7 to 10% of 
the patients with classical PKU responded to BH4 therapy.21 
BH4 therapy may be used as an adjunct to dietary restriction. 
However, BH4 is not registered in the Netherlands and may 
have uncertain long-term availability; also there is minimal 
clinical experience and the potential costs may be high. 
Another treatment that may be promising is the use 
of oral large neutral amino acids (LNAA). LNAA (e.g. 
phenylalanine, tyrosine, tryptophan, leucine, isoleucine) 
compete with each other at the blood brain barrier. High 
blood levels of LNAA can result in carrier saturation and 
competitive inhibition of Phe, resulting in a decrease in 
Phe.22 LNAA cross the intestinal mucosa by carrier proteins 
similar to those of the blood brain barrier. The affinity of the 
LNAA at the blood brain barrier is much higher than in the 
intestinal mucosa, so high concentrations must be present 
in the intestines in order to influence brain Phe levels.
A double-blind, randomised, controlled trial with LNAA 
therapy showed a significant decrease in blood Phe levels 
with a mean of 39% from the baseline (from 932 μmol/l to 
568 μmol/l).22 An advantage compared with BH4 therapy 
is the lowering of Phe levels in all PKU patients, not only 
in milder forms. LNAA therapy is not available in the 
Netherlands at present.
Brain Phe is deducted from the blood Phe levels, but a 
linear relation may not be present. New techniques to 
noninvasively assess brain Phe would be most welcome. 
At a more basic level, new modalities in PKU treatment 
are being studied, for example: somatic gene therapy 
and enzyme therapy.23-27 However, these efforts have not 
led to an effective treatment so far. Although all of the 
new approaches may be useful in the future, the dietary 
treatment of PKU remains the most important clinical 
tool in PKU.
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C o M P l i C A T i o N s  i N  A d U l T H o o d
The adult complications in PKU consist of two components. 
On the one hand complications of high Phe levels can 
be seen, such as neurological and (neuro)psychological 
problems. On the other hand, complications occur as a 
cause of dietary protein restriction, for example vitamin 
deficiencies and osteoporosis. 
N E U r o l o G Y/ N E U r o P s Y C H o l o G Y
Adults with PKU who were treated from early infancy 
have normal intelligence, but their neuropsychological 
test scores are somewhat lower than those of the general 
population, their parents, and unaffected siblings.28 
In many functional domains, such as motor speed, 
speech, language and some aspects of memory, treated 
PKU patients perform comparably with healthy controls. 
However, the domains of abstract reasoning, executive 
functioning, and attention have been identified as areas of 
weakness despite adhering to the diet.29 Even continuously 
treated PKU patients show decreased performance at 
neuropsychological tests, which improves when Phe levels 
are lowered by a more strict PKU diet.30 
Furthermore, adults with PKU who were continuously 
treated but relaxed the diet have displayed white matter 
abnormalities on structural magnetic resonance 
imaging,31,32 which are considered to be indicative of a 
reduction in myelin.33,34 These abnormalities disappear after 
reintroducing a strict diet. The hypothesis suggests that 
elevated Phe concentrations impact on myelin production 
and maintenance. Using a murine model, Dyer et al. have 
shown that Phe can inhibit the activity of HMG-CoA 
reductase, which leads oligodendrocytes to develop into 
non-myelinating oligodendrocytes. A strict diet on the 
other hand normalises the HMG-CoA reductase activity 
and produces myelinating oligodendrocytes.34 However, 
this theory has not yet been confirmed in humans. 
Neurological investigations in early-treated adults with 
PKU who discontinued the diet reveal a higher incidence 
of minor neurological signs including tremor, brisk deep 
tendon reflexes or clumsy motor co-ordination.31,35,36 In rare 
cases severe neurological deterioration may occur after 
cessation of dietary treatment. The symptoms, including 
spastic paresis, late-onset epilepsy, ataxia and tremor, are 
very similar to those of untreated PKU patients.35,37 Poor 
early control seems to be a risk factor in all reported cases. 
Neurological deterioration has not yet been reported in 
early-treated PKU patients.38 However, it cannot be excluded 
that further neurological deterioration could emerge 
later in life.36 In all patients with late-onset neurological 
deterioration it is mandatory to exclude a possible vitamin 
B12 deficiency.38
P s Y C H o l o G i C A l  P r o b l E M s
Severe behaviour and psychiatric problems are seen in 
profoundly retarded (untreated) adults with PKU in the 
third and fourth decade of life.39 With introduction of 
a Phe-restricted diet, these symptoms are sometimes 
reversible.40 It has been reported that early-treated 
adults with normal intelligence whose diet has been 
discontinued developed psychiatric and/or psychological 
problems, including depression, anxiety, social withdrawal, 
agoraphobia, low self-esteem, neurotic behaviour, and 
other phobias.41-43 Other studies have found no difference 
between PKU patients and sibling controls on psychological 
outcome.
Several studies showed reduced levels of noradrenalin and 
serotonin in PKU patients which has been linked to panic 
attacks,44 and depression or agoraphobia,45 respectively. 
High blood Phe levels lead to disturbances in dopaminergic 
and serotonergic neurotransmission through the same 
mechanism as described earlier.44,46,47 Koch et al. showed a 
clinical improvement in depressed PKU patients, who were 
treated with LNAA.48
V i T A M i N  d E f i C i E N C i E s
Vitamin B12 is only found in animal protein, the sources 
being meat, fish and poultry. Since the PKU diet is restricted 
in protein, vitamin B12 must be provided either combined 
with the amino acid supplement or from a separate 
supplement. Vitamin B12 deficiency can occur when PKU 
patients relax their diet in adolescence.15 They tend to choose 
products that are low in animal protein and amino acid 
supplements are not taken properly.49 Vitamin B6, folic 
acid and iron can also be deficient in a PKU diet, although 
it occurs less frequently than vitamin B12 deficiency. 
Methylmalonic acid (MMA) and homocysteine are both 
highly sensitive markers to assess vitamin B12 deficiency 
at tissue level.50
Vitamin B12 serves as a co-factor for two enzymes: 
L-methylmalonyl-coA mutase and methionine 
synthetase. Deficiency of vitamin B12 will lead to higher 
concentrations of homocysteine and MMA.50 Vitamin B12 
deficiency can cause a wide range of clinical symptoms 
including neuropathy, subacute combined degeneration 
of the cord, glossitis, anaemia, dementia and psychiatric 
states such as depression and psychoses.15 The clinical 
manifestations of a vitamin B12 deficiency appear years 
after the start of an inadequate intake.51 The large body 
storage, long half-life and the efficient re-absorption 
in the intestines are the main reasons.52 However, low 
serum vitamin B12 levels correlate in only 25 to 50% 
with a vitamin B12 deficiency at tissue level.53 Combined 
deficiencies of iron and vitamin B12 are frequently seen 
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in PKU patients, so haematological parameters such as 
haemoglobin and mean corpuscular volume are not good 
indicators for vitamin B12 deficiency.
o s T E o P o r o s i s
Osteoporosis is an important cause of morbidity and 
mortality in later life. Diagnosis is usually made following 
a fracture but may be preceded by an asymptomatic period 
of osteopenia. One of the predisposing factors to fracture 
is thought to be failure in achieving an optimal peak bone 
mass in early adult life.51 Modan-Moses et al. showed a 
decreased peak bone mass in PKU patients.52 Many other 
studies have shown a decreased bone mineral density 
(BMD) in patients with PKU.53-55 The exact mechanisms 
of osteopenia and osteoporosis in PKU and HPA 
patients remain unclear. Possible explanations include 
long-standing dietary deficiency in protein, calcium, 
vitamin D or trace elements, or a primary defect in bone 
turnover inherent to the disease itself.52 PKU patients may 
be at risk for osteoporosis in later life. However, there is no 
evidence that a life-long dietary treatment can prevent or 
treat osteoporosis.
M A T E r N A l  P H E N Y l K E T o N U r i A
One situation where a phenylalanine-restricted diet is 
mandatory is for women with PKU and HPA who are 
pregnant or planning a pregnancy. Charles Dent was one 
of the first physicians to recognise the teratogenic effects of 
maternal Phe on the foetus in 1956.56 These effects include 
mental retardation, facial dysmorphism, microcephaly, 
intrauterine growth retardation (IUGR), developmental 
delay and congenital heart disease (CHD).56,57 In untreated 
pregnancies of women with PKU and Phe levels ≥1200 
μmol/l, more than 90% of the offspring have microcephaly 
and mental retardation, 40% have IUGR and 12 to 15% 
have CHD. When the range of Phe is between 600 and 
1200 μmol/l these teratogenic effects are less frequent, and 
when dietary treatment lowers the blood Phe level to 120 to 
360 μmol/l, the offspring may be normal. This indicates a 
dose-response relation.58 
During pregnancy, the placenta naturally selects for 
higher concentrations of amino acids, including Phe. 
There is an active transplacental Phe gradient during 
pregnancy. Phe levels are amplified (1.5 to 2.0 times) 
which leads to high Phe levels in the foetal circulation.59 
During the early stages of embryogenesis high Phe 
levels can have a deleterious effect on neural crest cell 
migration, thereby explaining facial dysmorphisms and 
cardiac anomalies. During fetogenesis Phe has deleterious 
effects on neuronal multiplication and myelinisation.60 
However, these hypotheses have only been tested in 
animal studies. 
Not only the blood Phe levels are of importance. Too little 
maternal weight gain and low intake of either protein or 
calories can also interfere with foetal growth.61
The most important weapon for preventing embryopathy 
is preconceptional information, since a good metabolic 
state must be achieved before conception. However, it is 
still beneficial to the foetus to reduce levels within the first 
trimester in case of an unexpected pregnancy.
The Dutch guidelines recommend blood Phe levels of 120 
to 240 μmol/l in pregnancy. It is advised to determine Phe 
levels once or twice a week. After three months, tyrosine 
should be supplemented. The critical period for the nervous 
system, cranium and heart is at five to eight weeks of 
pregnancy. Consequently, good metabolic control must be 
achieved before week 5, to prevent teratogenic effects on the 
developing foetus.59 Recent data suggest that swings in blood 
Phe levels, even within the target ranges, have significant 
impact on the offspring neuropsychometric outcome.62 
Nowadays, few teratogenic effects on newborns are seen, 
thanks to good metabolic control. Hanley and colleagues 
have shown that a small number of untreated or poorly 
treated PKU pregnancies result in normal offspring, 
while a few apparently well-treated pregnancies are not 
successful. The exact mechanisms remain unclear. 
However, teratogenesis is a multi-factorial phenomenon 
with protective and toxic mechanisms, so that poorly treated 
PKU mothers can have normal offspring, and apparently 
well-treated PKU pregnancies are not successful.
r E C o M M E N d A T i o N s
PKU patients should be encouraged to remain on a 
lifelong diet and take their nutritional supplements. Blood 
Phe levels should be monitored every three months. It is 
recommended to do a clinical review on patients every 
year. Not only dietary status and blood Phe level should 
be monitored, but all other items in table 1 need to be 
considered. Full amino acid spectrum is recommended. A 
dedicated dietician should be part of the team caring for 
PKU patients. It is advised to assess bone marrow density 
(BMD) every two to five years. Treatment with calcium and 
vitamin D supplements should be given in every patient 
with PKU and a low BMD. Furthermore, women need 
to be informed about strict dietary control in (intended) 
pregnancy. All pregnant PKU patients should be under 
the control of a physician specialised in metabolic diseases, 
a dietician and a gynaecologist and should be offered a 
detailed ultrasound at 20 weeks of gestation. Pregnant 
PKU and HPA woman should be seen every three to four 
weeks and blood Phe levels must be monitored at least 
once a week.
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C o N C l U s i o N
PKU is a success story. Its ascertainment and treatment from 
early infancy has led to excellent outcomes. At the same time 
new problems occur with the PKU patients getting older. 
Knowledge of the adult issues in PKU will lead to a better 
understanding among clinicians and can overcome these 
difficulties, resulting in (almost) normal lives for PKU 
patients. Still many aspects of adult PKU remain unclear 
and need further elucidation in the near future.
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